Scribe Therapeutics advances STX-1150 Phase 1 trial, expands Sanofi deal
The gene-editing company reported continued enrollment in its lead cardiovascular program and said cash on hand funds operations into the first half of 2029.
Scribe Therapeutics reported third quarter 2026 results on November 12, 2026, highlighting progress across its cardiovascular pipeline. The first-in-human Phase 1 trial of STX-1150, initiated in mid-2026, remains ongoing, with clinical data expected in the first half of 2027.1 The study is evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of STX-1150 in adults with elevated LDL-C and increased ASCVD risk.1 The company said it anticipates reporting initial data, including safety, tolerability, and LDL-C lowering activity, from the single ascending dose portion of the trial in the first half of 2027.1
STX-1150 uses Scribe's ELXR epigenetic silencing platform. In a non-human primate study, a single dose of 0.75 mg/kg produced LDL-C reductions of greater than 50%, sustained for two years, with liver enzyme profiles comparable to saline controls.1 The company's second program, STX-1200, targets LPA using Scribe's X-Editor gene editing technology, and in preclinical studies STX-1200 surrogates achieved greater than 95% Lp(a) reduction in non-human primates.1
On the corporate side, Scribe expanded its multi-year research collaboration with Sanofi, providing Sanofi access to its ELXR epigenetic silencing technology in addition to its XE gene-editing technology and extending Sanofi's nomination period for target selection under the license agreement.1
Financially, cash, cash equivalents, and marketable securities were $174.2 million as of September 30, 2026, compared to $43.0 million as of June 30, 2026,1 an increase driven primarily by approximately $140.2 million of net proceeds from the July 2026 IPO and concurrent private placement, partially offset by cash used in operations.1 The company said this funding is expected to support operations into the first half of 2029.1 Net loss for the quarter was $9.9 million, or $0.68 per basic and diluted share, compared to a net loss of $6.5 million in the prior quarter.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.